International Journal of General Medicine (Aug 2021)
Construction of a Novel Lung Adenocarcinoma Immune-Related lncRNA Pair Signature
Abstract
Xiangjun Qi,1 Guoming Chen,1 Zhuangzhong Chen,2 Jing Li,1,3 Wenmin Chen,1 Jietao Lin,2 Lizhu Lin2,4 1The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of China; 2Department of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of China; 3Department of Oncology, The First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, People’s Republic of China; 4Cancer Project Team of China Center for Evidence Based Traditional Chinese Medicine, Guangzhou, People’s Republic of ChinaCorrespondence: Jietao Lin; Lizhu LinThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, No. 16 Jichang Road, Baiyun District, Guangzhou, 510405, People’s Republic of ChinaTel +86 20-36596356Email [email protected]; [email protected]: A growing number of studies have demonstrated that immune-related long noncoding ribonucleic acids (irlncRNAs) are potential prognostic factors for lung adenocarcinoma. Two-gene combination patterns could improve the sensitivity of prognostic models, providing us a novel signature construction concept that we applied to lung adenocarcinoma.Methods: Gene expression and clinical data were downloaded from the Lung Adenocarcinoma project of The Cancer Genome Atlas (TCGA) database. We applied a co-expression analysis with immune genes obtained from the ImmPort database to recognize irlncRNA. The matrix of irlncRNA pairs was established by a cyclic comparison of each lncRNA pair expression level. Univariate and multivariate Cox regressions and Lasso penalized regression analysis were applied to construct the risk model. Patients with lung adenocarcinoma were divided into high- and low-risk groups, according to the Akaike Information Criterion (AIC) values of the receiver operating characteristic (ROC) curve. Then, we evaluated our signature under various clinical settings: clinical-pathological characteristics, tumor-infiltrating immune cells, checkpoint-related biomarkers, targeted therapy, and chemotherapy.Results: Based on the 239 differently expressed irlncRNAs, we constructed an 11-irlncRNA pair signature. The area under the curve (AUC) of the ROC curve for the signature to predict the 4-year survival rate was 0.819, and the cut-off point was recognized as 1.003. Subsequent analysis showed that our signature can effectively distinguish unfavorable survival outcomes, prognostic clinic-pathological characteristics, and specify tumor infiltration status. Highly expressed immune checkpoint-related genes, as well as higher chemosensitivity, were correlated to the low-risk group.Conclusion: We constructed a novel lung adenocarcinoma irlncRNA signature with promising prognostic value using the TCGA database, based on paired irlncRNAs and not relying on lncRNAs special expression levels.Keywords: lung adenocarcinoma, immune-related lncRNA, immune infiltrate, survival analysis, prognosis
